Variability in non-invasive tests: Challenges and implications for monitoring liver disease

Background: Diagnostic and prognostic non-invasive fibrosis tests (NITs) are increasingly repurposed to monitor liver disease. However, their reproducibility and the minimal detectable change (MDC, ie, the smallest change that exceeds expected measurement variability) are poorly characterized. Methods: We retrospectively assessed variability of blood-based NITs and liver stiffness measurement (LSM) by vibration-controlled transient elastography on the same day (repeatability) and across use-cases when metabolic dysfunction–associated steatotic liver disease, fibrosis, or portal hypertension is suspected. Measurements were done within 90 days. Agreement and variability were quantified using intraclass correlation coefficients (ICC), Bland–Altman analyses, and MDC on the original (absolute) and relative (MDC%) scales. Results: Across 6 cohorts, ICCs were generally good to excellent, but within-subject variability remained substantial. Same-day LSM had a pooled MDC% of 24% on the m/s scale, corresponding to an asymmetric kPa-equivalent window of −43% to +54%. For longitudinal lab-based NITs, pooled MDC% was 47% for FIB-4 and 56% for APRI, while absolute MDC was 13–17 percentage points for LiverPRO and 3 percentage points for CORE. Optimistic estimates remained substantial after excluding the 10% most extreme paired differences. Variability increased with biomarker level for LSM, FIB-4, and APRI, whereas MDC windows for probability-based scores were strongly baseline-dependent and followed an inverse U-shaped pattern. When repeat testing was triggered by an elevated initial LSM, regression to the mean accounted for most or all of the observed decrease. Conclusions: Good agreement in NITs does not guarantee high precision for disease monitoring. MDC depends on biomarker level, clinical setting, measurement scale, and selection for repeat testing. Universal thresholds should not be applied uncritically, and repeated measurements, baseline-dependent interpretation, and regression to the mean should guide monitoring decisions.

Authors

Institutions

Publication Details

Journal
Hepatology Communications
Published
2026-11-11
DOI
https://doi.org/10.1097/hc9.0000000000001077
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Variability in non-invasive tests: Challenges and implications for monitoring liver disease

Mattias Mandorfer, Katrine Holtz Thorhauge, Peter Andersen, Patrick Haselwanter et al.
Hepatology Communications
Liver Disease Diagnosis and Treatment
article

Variability in non-invasive tests: Challenges and implications for monitoring liver disease

Mattias Mandorfer, Katrine Holtz Thorhauge, Peter Andersen, Patrick Haselwanter, Katrine Prier Lindvig, Robert Winker, Benedikt Mehl, Benedikt Simbrunner, Mads Egerod Israelsen, Lukas Hartl, Ida Falk Villesen, Aleksander Ahm Krag, Johanne Kragh Hansen, Maja Sofie Thiele, Georg Semmler, Thomas Reiberger, Benedikt Silvester Hofer, Michael A Trauner, Lorenz Balcar, Lucie Simonis, Thomas Matthias Scherzer, Jan Embacher, Philipp Hruska, Yannick Marcour, Paula Hoefinger, Adrian Wunderbaldinger, Mathias Jachs
article en

Abstract

Background: Diagnostic and prognostic non-invasive fibrosis tests (NITs) are increasingly repurposed to monitor liver disease. However, their reproducibility and the minimal detectable change (MDC, ie, the smallest change that exceeds expected measurement variability) are poorly characterized. Methods: We retrospectively assessed variability of blood-based NITs and liver stiffness measurement (LSM) by vibration-controlled transient elastography on the same day (repeatability) and across use-cases when metabolic dysfunction–associated steatotic liver disease, fibrosis, or portal hypertension is suspected. Measurements were done within 90 days. Agreement and variability were quantified using intraclass correlation coefficients (ICC), Bland–Altman analyses, and MDC on the original (absolute) and relative (MDC%) scales. Results: Across 6 cohorts, ICCs were generally good to excellent, but within-subject variability remained substantial. Same-day LSM had a pooled MDC% of 24% on the m/s scale, corresponding to an asymmetric kPa-equivalent window of −43% to +54%. For longitudinal lab-based NITs, pooled MDC% was 47% for FIB-4 and 56% for APRI, while absolute MDC was 13–17 percentage points for LiverPRO and 3 percentage points for CORE. Optimistic estimates remained substantial after excluding the 10% most extreme paired differences. Variability increased with biomarker level for LSM, FIB-4, and APRI, whereas MDC windows for probability-based scores were strongly baseline-dependent and followed an inverse U-shaped pattern. When repeat testing was triggered by an elevated initial LSM, regression to the mean accounted for most or all of the observed decrease. Conclusions: Good agreement in NITs does not guarantee high precision for disease monitoring. MDC depends on biomarker level, clinical setting, measurement scale, and selection for repeat testing. Universal thresholds should not be applied uncritically, and repeated measurements, baseline-dependent interpretation, and regression to the mean should guide monitoring decisions.

Hepatology CommunicationsVol. 10(12)
University of Southern Denmark (DK), Odense University Hospital (DK), Fachhochschule Wiener Neustadt (AT), Medical University of Vienna (AT)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon